Open drug discovery for the Zika virus [version 1; referees: 3 approved]
The Zika virus (ZIKV) outbreak in the Americas has caused global concern that we may be on the brink of a healthcare crisis. The lack of research on ZIKV in the over 60 years that we have known about it has left us with little in the way of starting points for drug discovery. Our response can build...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
F1000 Research Ltd
2016-02-01
|
| Series: | F1000Research |
| Subjects: | |
| Online Access: | http://f1000research.com/articles/5-150/v1 |
| _version_ | 1818514738182619136 |
|---|---|
| author | Sean Ekins Daniel Mietchen Megan Coffee Thomas P Stratton Joel S Freundlich Lucio Freitas-Junior Eugene Muratov Jair Siqueira-Neto Antony J Williams Carolina Andrade |
| author_facet | Sean Ekins Daniel Mietchen Megan Coffee Thomas P Stratton Joel S Freundlich Lucio Freitas-Junior Eugene Muratov Jair Siqueira-Neto Antony J Williams Carolina Andrade |
| author_sort | Sean Ekins |
| collection | DOAJ |
| description | The Zika virus (ZIKV) outbreak in the Americas has caused global concern that we may be on the brink of a healthcare crisis. The lack of research on ZIKV in the over 60 years that we have known about it has left us with little in the way of starting points for drug discovery. Our response can build on previous efforts with virus outbreaks and lean heavily on work done on other flaviviruses such as dengue virus. We provide some suggestions of what might be possible and propose an open drug discovery effort that mobilizes global science efforts and provides leadership, which thus far has been lacking. We also provide a listing of potential resources and molecules that could be prioritized for testing as in vitro assays for ZIKV are developed. We propose also that in order to incentivize drug discovery, a neglected disease priority review voucher should be available to those who successfully develop an FDA approved treatment. Learning from the response to the ZIKV, the approaches to drug discovery used and the success and failures will be critical for future infectious disease outbreaks. |
| first_indexed | 2024-12-11T00:19:54Z |
| format | Article |
| id | doaj.art-a25d8021d75548d2a69e93f71fdc0e14 |
| institution | Directory Open Access Journal |
| issn | 2046-1402 |
| language | English |
| last_indexed | 2024-12-11T00:19:54Z |
| publishDate | 2016-02-01 |
| publisher | F1000 Research Ltd |
| record_format | Article |
| series | F1000Research |
| spelling | doaj.art-a25d8021d75548d2a69e93f71fdc0e142022-12-22T01:27:48ZengF1000 Research LtdF1000Research2046-14022016-02-01510.12688/f1000research.8013.18622Open drug discovery for the Zika virus [version 1; referees: 3 approved]Sean Ekins0Daniel Mietchen1Megan Coffee2Thomas P Stratton3Joel S Freundlich4Lucio Freitas-Junior5Eugene Muratov6Jair Siqueira-Neto7Antony J Williams8Carolina Andrade9Collaborative Drug Discovery Inc., Burlingame, CA, USAOpen Knowledge Foundation Deutschland e.V., Berlin, GermanyThe International Rescue Committee , NY, NY, USADepartment of Pharmacology, Physiology and Neuroscience, Rutgers University-New Jersey Medical School, Newark, NJ, USADivision of Infectious Diseases, Department of Medicine, and the Ruy V. Lourenço Center for the Study of Emerging and Re-emerging Pathogens, Rutgers University–New Jersey Medical School, Newark, NJ, USAChemical Biology and Screening Platform, Brazilian Laboratory of Biosciences (LNBio), CNPEM, Campinas, BrazilLaboratory for Molecular Modeling, Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USASkaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego, CA, USAChemConnector, Wake Forest, NC, USALabMol - Laboratory for Molecular Modeling and Drug Design, Faculty of Pharmacy, Federal University of Goias, Goiânia, BrazilThe Zika virus (ZIKV) outbreak in the Americas has caused global concern that we may be on the brink of a healthcare crisis. The lack of research on ZIKV in the over 60 years that we have known about it has left us with little in the way of starting points for drug discovery. Our response can build on previous efforts with virus outbreaks and lean heavily on work done on other flaviviruses such as dengue virus. We provide some suggestions of what might be possible and propose an open drug discovery effort that mobilizes global science efforts and provides leadership, which thus far has been lacking. We also provide a listing of potential resources and molecules that could be prioritized for testing as in vitro assays for ZIKV are developed. We propose also that in order to incentivize drug discovery, a neglected disease priority review voucher should be available to those who successfully develop an FDA approved treatment. Learning from the response to the ZIKV, the approaches to drug discovery used and the success and failures will be critical for future infectious disease outbreaks.http://f1000research.com/articles/5-150/v1Drug Discovery & DesignTropical & Travel-Associated DiseasesVirology |
| spellingShingle | Sean Ekins Daniel Mietchen Megan Coffee Thomas P Stratton Joel S Freundlich Lucio Freitas-Junior Eugene Muratov Jair Siqueira-Neto Antony J Williams Carolina Andrade Open drug discovery for the Zika virus [version 1; referees: 3 approved] F1000Research Drug Discovery & Design Tropical & Travel-Associated Diseases Virology |
| title | Open drug discovery for the Zika virus [version 1; referees: 3 approved] |
| title_full | Open drug discovery for the Zika virus [version 1; referees: 3 approved] |
| title_fullStr | Open drug discovery for the Zika virus [version 1; referees: 3 approved] |
| title_full_unstemmed | Open drug discovery for the Zika virus [version 1; referees: 3 approved] |
| title_short | Open drug discovery for the Zika virus [version 1; referees: 3 approved] |
| title_sort | open drug discovery for the zika virus version 1 referees 3 approved |
| topic | Drug Discovery & Design Tropical & Travel-Associated Diseases Virology |
| url | http://f1000research.com/articles/5-150/v1 |
| work_keys_str_mv | AT seanekins opendrugdiscoveryforthezikavirusversion1referees3approved AT danielmietchen opendrugdiscoveryforthezikavirusversion1referees3approved AT megancoffee opendrugdiscoveryforthezikavirusversion1referees3approved AT thomaspstratton opendrugdiscoveryforthezikavirusversion1referees3approved AT joelsfreundlich opendrugdiscoveryforthezikavirusversion1referees3approved AT luciofreitasjunior opendrugdiscoveryforthezikavirusversion1referees3approved AT eugenemuratov opendrugdiscoveryforthezikavirusversion1referees3approved AT jairsiqueiraneto opendrugdiscoveryforthezikavirusversion1referees3approved AT antonyjwilliams opendrugdiscoveryforthezikavirusversion1referees3approved AT carolinaandrade opendrugdiscoveryforthezikavirusversion1referees3approved |